Ionis Pharmaceuticals, Inc. (IONS) Positive CORE And CORE2 Topline Results (Transcript)

Core Insights - The conference call discusses the top line results from the CORE and CORE2 studies of olezarsen in patients with severe hypertriglyceridemia (sHTG) [2] - Full data from the Phase III Essence Study of olezarsen in patients with moderate hypertriglyceridemia (HTG) were presented at the 2025 ESC Congress [3] Company Information - Ionis has released a press release and accompanying slides regarding the olezarsen studies, available on their website [2] - The call is led by Wade Walke, Senior Vice President of Investor Relations, indicating the importance of the results being discussed [1]